Respiratory Medicine
Volume 104, Issue 10 , Pages 1450-1459 , October 2010

Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD

  • Heinrich Worth

      Affiliations

    • Medical Department I, Fürth Hospital, 90766 Fürth, Germany
    • Corresponding Author InformationCorresponding author. Klinikum Fürth, Akademisches Lehrkrankenhaus der Universität Erlangen-Nürnberg, Jakob-Henle-Str. 1, 90766 Fürth, Germany. Tel.: +49 911 7580 1101; fax: +49 911 7580 1141.
    • ,
  • Karin Förster

      Affiliations

    • Department of Cardiology, Pneumology and Allergology, Practice Dr. Förster, 10367, Berlin, Germany
    • ,
  • Göran Eriksson

      Affiliations

    • AstraZeneca R&D, Lund SE-21187, Sweden
    • Department of Respiratory Medicine and Allergology, University Hospital, Lund SE-21187, Sweden
    • ,
  • Ulf Nihlén

      Affiliations

    • AstraZeneca R&D, Lund SE-21187, Sweden
    • Department of Respiratory Medicine and Allergology, University Hospital, Lund SE-21187, Sweden
    • ,
  • Stefan Peterson

      Affiliations

    • AstraZeneca R&D, Lund SE-21187, Sweden
    • ,
  • Helgo Magnussen

      Affiliations

    • Pulmonary Research Institute, Grosshansdorf Hospital, Centre for Pneumology and Thoracic Surgery, Grosshansdorf D-22927, Germany

Received 24 February 2010 ,Accepted 9 July 2010.

References 

  1. Global Initiative for Chronic Obstructive Lung Disease . Global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. 2008. 19-12-2008;
  2. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin. 2009;25:2043–2048
  3. O’Donnell DE. Impacting patient-centred outcomes in COPD: breathlessness and exercise tolerance. Eur Respir Rev. 2006;15:37–41
  4. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J. 2003;21:86–94
  5. Bouros D, Kottakis J, Le Gros V, Overend T, Della CG, Siafakas N. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV (1) reversibility. Curr Med Res Opin. 2004;20:581–586
  6. Fuso L, Incalzi RA, Basso S, Spadaro S, Tramaglino LM, Trove A, et al. Effects of formoterol inhaled dry powder on exercise performance in chronic obstructive pulmonary disease: a single-center, randomized, double-blind, placebo-controlled, crossover study. Curr Ther Res. 2003;64:317–326
  7. Neder JA, Fuld JP, Overend T, Thirlwell J, Carter R, Stevenson R, et al. Effects of formoterol on exercise tolerance in severely disabled patients with COPD. Respir Med. 2007;101:2056–2064
  8. Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:580–584
  9. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J. 2000;320:1297–1303
  10. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:122–128
  11. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23:698–702
  12. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology. 2007;12:732–739
  13. Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449–456
  14. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74–81
  15. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912–919
  16. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68:1975–2000
  17. Cazzola M, Di Marco F, Santus P, Boveri B, Verga M, Matera MG, et al. The pharmacodynamic effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm Pharmacol Ther. 2004;17:35–39
  18. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Ramachandran S, Martin UJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69:549–565
  19. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest. 2006;130:647–656
  20. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31:416–468
  21. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD. 2005;2:131–136
  22. O’Donnell DE, Travers J, Webb KA, He Z, Lam YM, Hamilton A, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J. 2009;34:866–874
  23. Berry MJ. The relationship between exercise tolerance and other outcomes in COPD. COPD. 2007;4:205–216
  24. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887
  25. O’Donnell DE. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:180–184
  26. O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004;23:832–840
  27. Mador MJ, Bozkanat E. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Respir Res. 2001;2:216–224
  28. Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J. 2007;29:587–595
  29. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol. 1995;268:L41–L46
  30. Cazzola M, Santus P, Di Marco F, Carlucci P, Mondoni M, Matera MG, et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther. 2004;17:121–125
  31. Sun HW, Miao CY, Liu L, Zhou J, Su DF, Wang YX, et al. Rapid inhibitory effect of glucocorticoids on airway smooth muscle contractions in guinea pigs. Steroids. 2006;71:154–159
  32. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, et al. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev. 2003;83:965–1016
  33. Losel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4:46–56
  34. Cazzola M, Noschese P, De Michele F, D’Amato G, Matera MG. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med. 2006;100:212–217
  35. Wanner A, Horvath G, Brieva JL, Kumar SD, Mendes ES. Nongenomic actions of glucocorticosteroids on the airway vasculature in asthma. Proc Am Thorac Soc. 2004;1:235–238
  36. VanHelder T, Radomski MW. Sleep deprivation and the effect on exercise performance. Sports Med. 1989;7:235–247
  37. Maltais F, Hamilton A, Marciniuk D, Hernandez P, Sciurba FC, Richter K, et al. Improvements in symptom-limited exercise performance over 8 h with Once-daily tiotropium in patients with COPD. Chest. 2005;128:1168–1178

PII: S0954-6111(10)00325-2

doi: 10.1016/j.rmed.2010.07.006

Respiratory Medicine
Volume 104, Issue 10 , Pages 1450-1459 , October 2010

Article Tools

* Image Usage & Resolution